average monthly weight loss on glp 1 GLP-1 medications are changing the landscape of obesity treatment, but having realistic expectations is really important. Clinical trials showed weight loss of approximately: • ~15% body weight with semaglutide • ~ GLP-1 Medication - Weight Loss

But the other 40% is something far more insidious

Among the observations from microdosing patients, some have reported non-scale changes they attribute to reduced inflammation

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

Concerning IBS, including its constipation-predominant variant (IBS-C), the aggregate benefit derived from probiotic supplementation is typically marginal (392)

2023 Aug;47(8):677-685

In another study, the same treatment in 19 participants with obesity and diabetes was associated with an improved MoCA score, olfactory test total score and enhanced odor-induced right parahippocampus activation 46